Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Inhibrx, a Phase 1 biotech developing single domain antibodies for cancer and rare diseases, raised $119 million by offering 7 million shares at $17, the midpoint of the range of $16 to $18. The company offered 1 million more shares than anticipated. ...read more
Updated Monday, 8/17.
Three biotechs, a medical imaging company, and three SPACs are scheduled to go public in the week ahead. While the annual summer slowdown is setting in, the IPO market is still in the midst of its most active August since...read more
Inhibrx, a Phase 1 biotech using protein engineering to develop targeted therapies for cancer and rare diseases, announced terms for its IPO on Wednesday. The company previously filed to raise $75 million in June 2019 and withdrew the following November.
...read more
US IPO Weekly Recap: Biotechs and SPACs ride the summer wave in a 4 IPO week
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Oncology biotech Inhibrx prices upsized IPO at $17 midpoint
Inhibrx, a Phase 1 biotech developing single domain antibodies for cancer and rare diseases, raised $119 million by offering 7 million shares at $17, the midpoint of the range of $16 to $18. The company offered 1 million more shares than anticipated. ...read more
US IPO Week Ahead: The IPO market's summer slowdown approaches in a 4 IPO week
Updated Monday, 8/17. Three biotechs, a medical imaging company, and three SPACs are scheduled to go public in the week ahead. While the annual summer slowdown is setting in, the IPO market is still in the midst of its most active August since...read more
Oncology biotech Inhibrx sets terms for $102 million IPO
Inhibrx, a Phase 1 biotech using protein engineering to develop targeted therapies for cancer and rare diseases, announced terms for its IPO on Wednesday. The company previously filed to raise $75 million in June 2019 and withdrew the following November. ...read more